Enhancing cGMP in experimental progressive renal fibrosis: Soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition

American Journal of Physiology - Renal Physiology

Volumn 290, Issue 1, 2006, Pages

  Wang, Yingrui ^a,b   Krämer, Stephanie ^a   Loof, Tanja ^a   Martini, Sebastian ^a   Kron, Susanne ^a   Kawachi, Hiroshi ^c   Shimizu, Fuijo ^c   Neumayer, Hans H ^a   Peters, Harm ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b SUN YAT SEN UNIVERSITY   (China)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

BAY 41 2272; Pentoxifylline; Progression; TGF 1

Indexed keywords

(5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] PYRIMIDIN 4 YLAMINE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; MESSENGER RNA; NITRIC OXIDE; PADGEM PROTEIN; PENTOXIFYLLINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; 3 (4 AMINO 5 CYCLOPROPYLPYRIMIDINE 2 YL) 1 (2 FLUOROBENZYL) 1H PYRAZOLO(3,4 B)PYRIDINE; 3-(4-AMINO-5-CYCLOPROPYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDINE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; FLUID INTAKE; FOOD INTAKE; GLOMERULOSCLEROSIS; KIDNEY FIBROSIS; KIDNEY FUNCTION; MACROPHAGE FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; COMPARATIVE STUDY; DRINKING; DRUG EFFECT; ENZYMOLOGY; FIBROSIS; GLOMERULONEPHRITIS; IMMUNOLOGY; KIDNEY; MACROPHAGE; METABOLISM; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CELL PROLIFERATION; CYCLIC GMP; DRINKING; FIBROSIS; GLOMERULONEPHRITIS; GUANYLATE CYCLASE; KIDNEY; MACROPHAGES; MALE; NITRIC OXIDE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEINURIA; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR;

EID: 33644811885     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00197.2005     Document Type: Article

References (26)

1. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, and Hobbs AJ. Anti-inflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 101: 1386-1391, 2004.
2. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, and Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 100: 292-298, 1999.
3. Chen YM, Chien CT, Hu Tsai MI, Wu KD, Tsai CC, Wu MS, and Tsai TJ. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 56: 932-943, 1999.
4. Hohenstein B, Daniel C, Wagner A, Stasch JP, and Hugo C. Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol 288: F685-F693, 2005.
5. Kagota S, Tamashiro A, Yamaguchi Y, Sugiura R, Kuno T, Nakamura K, and Kunitomo M. Downregulation of vascular soluble guanylate cyclase induced by high salt intake in spontaneously hypertensive rats. Br J Pharmacol 134: 737-744, 2001.
6. Koesling D. Modulators of soluble guanylyl cyclase. Naunyn Schmiedebergs Arch Pharmacol 358: 123-126, 1998.
7. Krämer S, Loof T, Martini S, Rückert M, Wang Y, Böhler T, Shimizu F, Kawachi H, Neumayer HH, and Peters H. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis, but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol 289: F359-F368, 2005.
8. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ, Chen YM, Chien CT, Hu Tsai MI, Wu KD, Tsai CC, Wu MS, and Tsai TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 13: 2916-2929, 2002.
9. Marques M, Millas I, Jimenez A, Garcia-Colis E, Rodriguez-Feo JA, Velasco S, Barrientos A, Casado S, and Lopez-Farre A. Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J Am Soc Nephrol 12: 2594-2600, 2001.
10. Mayer B and Koesling D. cGMP signalling beyond nitric oxide. Trends Pharmacol Sci 22: 546-548, 2001.
11. McDonald LJ and Murad F. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med 211: 1-6, 1996.
12. Meskini N, Nemoz G, Okyayuz Baklouti I, Lagarde M, and Prigent AF. Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem Pharmacol 47: 781-788, 1994.
13. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, and Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90: E58-E65, 2002.
14. Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H, and Shimizu F. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 55: 877-889, 1999.
15. Ostendorf T, Kunter U, Grone HJ, Bahlmann F, Kawachi H, Shimizu F, Koch KM, Janjic N, and Floege J. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 12: 909-918, 2001.
16. Peters H, Border WA, and Noble NA. From rats to men: a perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant 14: 1640-1650, 1999.
17. Peters H, Daig U, Martini S, Ruckert M, Schaper F, Liefeldt L, Kramer S, and Neumayer HH. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney Int 64: 509-518, 2003.
18. Peters H, Martini S, Wang Y, Shimizu F, Kawachi H, Krämer S, and Neumayer HH. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy1 glomerulosclerosis. Kidney Int 66: 1434-1443, 2004.
19. Peters H, Martini S, Woydt R, Rückert M, Shimizu F, Kawachi H, Liefeldt L, Krämer S, and Neumayer HH. Moderate alcohol intake has no impact on acute and chronic progressive anti-thy1 glomerulonephritis. Am J Physiol Renal Physiol 284: F1105-F1114, 2003.
20. Peters H, Wang Y, Loof T, Martini S, Kron S, Krämer S, and Neumayer HH. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis. Kidney Int 66: 2224-2236, 2004.
21. Ruetten H, Zabel U, Linz W, and Schmidt HH. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 85: 534-541, 1999.
22. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, and Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 410: 212-215, 2001.
23. Theilig F, Bostanjoglo M, Pavenstadt H, Grupp C, Holland G, Slosarek I, Gressner AM, Russwurm M, Koesling D, and Bachmann S. Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver. J Am Soc Nephrol 12: 2209-2220, 2001.
24. Wada Y, Morioka T, Oyanagi-Tanaka Y, Yao J, Suzuki Y, Gejyo F, Arakawa M, and Oite T. Impairment of vascular regeneration precedes progressive glomerulosclerosis in anti-thy 1 glomerulonephritis. Kidney Int 61: 432-443, 2002.
25. Wang Y, Krämer S, Loof L, Martini S, Kron S, Shimizu F, Kawachi H, Neumayer HH, and Peters H. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int 68: 47-61, 2005.
26. Witte K, Jacke K, Stahrenberg R, Arlt G, Reitenbach I, Schilling L, and Lemmer B. Dysfunction of soluble guanylyl cyclase in aorta and kidney of Goto-Kakizaki rats: influence of age and diabetic state. Nitric Oxide 6: 85-95, 2002.